These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23466871

  • 1. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
    Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J.
    Cancer Imaging; 2013 Mar 05; 13(1):73-80. PubMed ID: 23466871
    [Abstract] [Full Text] [Related]

  • 2. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Hendel HW.
    J Nucl Med; 2013 Jul 05; 54(7):1026-31. PubMed ID: 23572497
    [Abstract] [Full Text] [Related]

  • 3. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021 Jul 05; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 4. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan 05; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 5. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A.
    PLoS One; 2018 Jan 05; 13(7):e0199529. PubMed ID: 30011328
    [Abstract] [Full Text] [Related]

  • 6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 05; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 7. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 05; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 8. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
    Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.
    J Nucl Med; 2019 Mar 05; 60(3):328-334. PubMed ID: 30030343
    [Abstract] [Full Text] [Related]

  • 9. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 10. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
    Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2021 Jun 20; 48(6):1932-1943. PubMed ID: 33336264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W, Liu C, Gu B, Zhang J, Lu L, Pan H, Yao Z, Wang M, Song S, Zhang Y, Yang Z.
    Nucl Med Commun; 2020 Mar 20; 41(3):280-287. PubMed ID: 32032193
    [Abstract] [Full Text] [Related]

  • 13. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
    Inal A, Kucukoner M, Kaplan MA, Urakci Z, Nas N, Guven M, Dostbil Z, Altindag S, Isikdogan A.
    Rev Port Pneumol; 2013 Mar 20; 19(6):260-5. PubMed ID: 23993406
    [Abstract] [Full Text] [Related]

  • 14. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, Yang CT, Cheng NM, Su TP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Nov 20; 43(12):2155-2165. PubMed ID: 27260520
    [Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
    Dhull VS, Sharma P, Sharma DN, Maharjan S, Suman Kc S, Patel C, Bal C, Kumar R.
    Int J Gynecol Cancer; 2014 Feb 20; 24(2):312-20. PubMed ID: 24407578
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY, Guo Z, Li YY, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2017 Nov 23; 39(11):828-834. PubMed ID: 29151289
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer.
    Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT.
    Cancer Imaging; 2014 Apr 22; 14(1):2. PubMed ID: 25609313
    [Abstract] [Full Text] [Related]

  • 19. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
    Nasir Z, Mahmood T, Adel H, Nausheen S, Hamid S, Sattar A, Manohar M.
    Cureus; 2019 Aug 18; 11(8):e5422. PubMed ID: 31632874
    [Abstract] [Full Text] [Related]

  • 20. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 18; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.